

THE SINO-AMERICAN PHARMACEUTICAL PROFESSIONALS
ASSOCIATION CONNECTICUT (SAPA-CT)
3RD ANNUAL CONFERENCE



Bringing Value to Patients through Technology Advancements and Global Innovations



Oct. 8th, 2016

Omni Hotel at Yale, New Haven, CT

Co-organizers:



耶魯大學中國學生學者聯合會
Association of Chinese Students and Scholars at Yale



Agenda

8:00 – 8:30 am Registration

Welcome

(8:30 – 9:00 am)

8:30 – 8:40 am

Liang Luo, Ph.D., President, SAPA-CT (2015-2016): Congratulations

Steven Yu, Ph.D., M.B.A., President, SAPA-CT (2016-2017)

Li Wang, Ph.D., Secretary: Announcement of SAPA-CT Election Results

8:40 – 8:45 am

Lei Tang, Ph.D., President, SAPA Headquarters

8:45 – 8:50 am

Jijun Xing, Ph.D., Science and Technology Counselor at Chinese Consulate-General in New York

8:50 – 8:55 am

Paul Edelberg, J.D., Partner, Fox Rothschild LLP. President, Connecticut China Council

8:55 – 9:00 am

Susan Froshauer, Ph.D., President and CEO, CURE-Connecticut United for Research Excellence

Honorary Speech

(9:00 – 9:40 am)

9:00 – 9:40 am

Henry C. Lee 李昌钰, Ph.D., Founder of The Henry C. Lee Institute of Forensic Science, the Director of Forensic Research and Training Center, and Distinguished Chair Professor in Forensic Science of University of New Haven
“Famous Cases Revised in Forensic Field”

Section 1 : Pharma Regulation and Global Development

(9:40 – 12:20 pm)

9 :40 – 10:10 am **Keynote Speech**

Yung-Chi Cheng, Ph.D., Henry Bronson Professor of Pharmacology at Yale University & Member of Academia Sinica, Republic of China

“Convergence of Paradigms of Western Medicine and Traditional Chinese Medicine in Developing Future Medicine”

10:10 – 10:40 am

Break

10:40 - 11:05 am

Ruchin Kansal, M. Arch., M.B.A., Executive Director and Head, Business Innovation, Boehringer Ingelheim

“From Industrial to Digital: Innovation for the New Age”

11:05 - 11:30 am

David Cragin, Ph.D., Associate Director, Chemical Notification and Registration, Merck

“Emerging Health Threats in China: Challenges and Solutions”

11:30 - 11:55 pm

Vincent Li, Ph.D., Office of Life Cycle Products, Office of Pharmaceutical Quality, CDER, FDA

“Ophthalmic Generic Product Development: Where Science and Regulatory Requirement Meet”

11:55 - 12:20 pm

Chris Mix, M.D., Executive Director, Global Medical Sciences, Alexion Pharmaceuticals

“Overview of Clinical Development, with Case Studies in Phase 3”

12:30 – 1:30 pm Complementary Lunch

Lunch Talk: Shaojing Hu, Ph.D., Vice President and Chief Chemist, Betta Pharmaceuticals Co., Ltd

“Oncology Drug R&D in China”

Honorary Speech

(1:30 – 2:00 pm)

1:30 – 2:00 pm

Ying Wang 王英, M.S., Board of Directors, Chongqing Lummy Pharmaceutical Co., Ltd.

“Introduction of the Bio-Pharmaceutical Intellectual Property Platform”

Section 2: Patent Law and Practice in Biotech & Pharma Industry

(2:00 – 3:15 pm)

2:00 – 2:25 pm

Shengju Deng 邓声菊, M.S., Vice President, Beijing Guozhi Patent Warning Consulting Co. Ltd

“How to Help Foreign Company to Protect its IP in China”

2:25 – 2:50 pm

Anthony Sabatelli, J.D., Ph.D., Partner, Dilworth IP, LLC

“Patent Overview for the Life Science”

2:50 – 3:15 pm

Alan Morrison, J.D., M. Phil., Founder, Law Offices of Alan J. Morrison

“Patent Inventorship in the United States, and Why It Matters”

3:15 – 3:45 pm

Break

Section 3: Pharma Industry Trend: R&D, Big Data and Precision Medicine

(3:45 – 6:20 pm)

3:45 – 4:15 pm **Keynote Speech**

Jiaying Hu, Ph.D., Program Director, Center for Computational Health, Distinguished Research Staff Member, Member in IBM Industry Academy, Fellow, IEEE, IAPR

IBM T.J. Watson Research Center

“Data Driven Healthcare Analytics”

4:15 – 4:40 pm

Qichao Zhu, Ph.D., Associate Professor Genetics & Genomic Science, Mount Sinai Hospital

“Personalized cancer medicine and its dependent data integration”

4:40 – 5:05 pm

Weibin Chen, Ph.D., Director in Scientific Operations, Waters Corporation

“Platform Technologies for Fingerprinting Biosimilars”

5:05 – 5:30 pm

Min Li, Ph.D., Vice President, Analytical Operation, Huahai Pharmaceutical Co., Ltd.

“The Pursuit of a Scientific Research Career in Pharmaceutical Industry – A Personal Journey from US to China”

5:30 – 5:55 pm

James Jin, Ph.D., Vice President, Biocytogen

“Biocytogen CRISPR/Cas9 Gene-Targeting Technology and Services”

5:55 – 6:20 pm

Meifang Xu, M.S., M.B.A., Shanghai Jiading Incubation Center; Chairman, the Community Charity Foundation of Jiading Industrial Zone

“Introduction of Shanghai Jiading Advanced Technology Innovation and Business”

7:00 – 9:00 pm Dinner

Omni Hotel at Yale, New Haven, CT

Dinner Talk: John Tan, Ph.D., President, Kelun U.S. Pharmaceutical Research Institute

“Kelun – Drive Biopharmaceutical Innovation in and Beyond China”

Speaker Biography



Lei Tang, Ph.D.

President,
SAPA Headquarters

Lei Tang is the Director of Global Scientific Affairs – PKDM at SANOFI. Lei received a B.Sc in Biochemistry from Peking University and a Ph.D. in Molecular and Cell Biology from Washington University School of Medicine at St Louis. During her 20-year tenure at SANOFI, Lei has held increasing responsibilities along the value chain of drug Discovery and Development. Currently, Lei manages global PKDM project portfolio and external sciences and innovations. She also serves as a Biological Assay, BioMarker and Translational Medicine expert to support projects, advisory groups and out-sourced studies. Since 2012, Lei has served as a member of SAPA Executive Committee and is the 2016-2017 SAPA President.



Jijun Xing, Ph.D.

Science and Technology Counselor,
Chinese Consulate-General in New York

Dr. Xing Jijun, Science and Technology Counselor in Chinese Consulate-General in New York. He received a bachelor degree of engineering, Tianjing University, a master degree in economics, People's University of China and a PhD in administrative management, Huazhong S&T University. Dr. Xing has years of experience since 1990 in managing and facilitating international scientific and technological cooperation. He served in Chinese Embassies in Norway and the Netherlands, Director of Asia and Africa and Director of Europe in the Chinese Ministry of Science and Technology (MOST). Before taking the current position, Dr. Xing served China Science and Technology Exchange Center as Deputy Director General covering governmental and non-governmental cooperation in science and technology, technology transfer and academic exchanges. His personal academic interest includes low carbon development technologies and low cost health technologies etc. Dr. Xing is now still a strategic evaluation expert for international cooperation under European Horizon 2020 program.



Paul Edelberg, J.D.

Partner,
Fox Rothschild LLP.
President,
Connecticut China Council

For more than three decades, Paul's practice has focused on corporate and commercial law for privately owned businesses, with an emphasis on general business counseling, commercial finance, mergers and acquisitions, private equity and venture capital and international trade and cross-border transactions. He also has a niche practice representing community banks in bank regulatory, compliance, lending and workout matters. His multifaceted practice enables him to serve the domestic and international needs of a wide range of clients, particularly those with interests in China. Paul has counseled clients on business structuring and outsourcing transactions in China, international trade and finance matters, U.S. export controls on sales to China and acquisitions of Chinese companies. Paul also counsels both U.S. companies doing business overseas and foreign companies doing business in the United States in matters involving: International private equity and venture capital transactions, Cross-border structuring, International debt and equity financing transactions, Trade and trade finance, Sales distribution agreements, Export control compliance, Joint ventures, Foreign Corrupt Practice Act (FCPA) compliance, EB-5 Regional Centers, CFIUS filings.

Paul is the former chairman of the Stamford Chamber of Commerce, is the founder and former chairman of its International Trade Council and is president of the Connecticut China Council. Paul is also Co-Chair of the American Bar Association International Law Section's China Committee and liaison to the Shandong Lawyers Association. He is a member of the Connecticut District Export Council and the U.S.-China Center Advisory Board of the Connecticut Board of Regents. Paul is recognized within the State of Connecticut and the City of Stamford for both his professional and community activities, and has taken a leadership role in China and international activities on a local and statewide basis.



Susan Froshauer, Ph.D.

President and CEO,
CURE-Connecticut United for Research Excellence

Dr. Froshauer is President and CEO of CURE (Connecticut United for Research Excellence, Inc.) and President of CURE Innovations, LLC. She has spent over 27 years in biopharmaceuticals research and development. She is an experienced scientist, pharmaceutical executive, mentor, entrepreneur and angel investor with skill at connecting academic expertise and technology with the commercial sector.

Susan is involved with the Yale Entrepreneurial Institute, the CTNext funded group, SECT Tech, the Creative Arts Workshop and the Angel Investor Forum. Prior to joining CURE, Dr. Froshauer was Director of the Technology Exchange Portal at the University of Connecticut's Office of Economic Development. In this role Susan assisted Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connected ideas with business expertise, business plans with investors and industry with scholars.

Until 2010, Susan served as President and CEO of Rib-X Pharmaceuticals, which she co-founded with Yale scientists in New Haven in 2000. Under her leadership, Rib-X raised more than \$160 million in private equity, bridge financing and government grants and built an emerging pipeline of antibiotics to treat serious antibiotic-resistant bacterial infections. Prior to Rib-X, for 5 years Susan served as a member of Pfizer's Strategic Alliance Group where she was part of a team involved in the creation of a \$200 million investment portfolio that transformed the Pfizer global research and development strategy, helping the company identify new resources for drug discovery. Prior to work at Pfizer in business development. Dr. Froshauer ran a drug discovery research lab responsible to identify new classes of antibiotics.

Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B. A. from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child's Fellow.



Henry C. Lee, Ph.D.

Founder ,
Henry C. Lee Institute of Forensic Science
Director,
Forensic Research and Training Center
Distinguished Chair Professor,
Forensic Science of University of New Haven

Dr. Henry C. Lee is one of the world's foremost forensic scientists. Dr. Lee's work has made him a landmark in modern-day forensic sciences. He has been a prominent player in many of the most challenging cases of the last 50 years. Dr. Lee has worked with law enforcement agencies from 46 countries in helping to solve more than 8000 cases. In recent years, his travels have taken him to England, Bosnia, Bermuda, China, Taiwan, Germany, Singapore, Croatia, Brunei, Thailand, Middle East, South America and other locations around the world.

Dr. Lee's testimony figured prominently in the O. J. Simpson, Jason Williams, Peterson, and Kennedy Smith trials, and in convictions of the "Wood chipper" murderer as well as thousands of other murder cases. Dr. Lee has assisted local and state police in their investigations of other famous crimes, such as the murder of Jon Benet Ramsey in Boulder, Colorado, the 1993 suicide of White House Counsel Vincent Foster, Kidnapping of Elizabeth Smart, Death of Chemdra Levy, the reinvestigation of the Kennedy assassination and the Casey Anthony case. He was a consultant for more than 800 law enforcement and judicial agencies.

Dr. Lee is the Founder of The Henry C. Lee Institute of Forensic Science, the Director of Forensic Research and Training Center and Distinguished Chair Professor in Forensic Science of University of New Haven. He was the Chief Emeritus for Connecticut State Police during 2000 to 2010 and was the Commissioner of Public Safety and State Police for the State of Connecticut during 1998 to 2000 and has served as that state's Chief Criminalist and Director of State Police Forensic laboratory from 1978 to 2000. Dr. Lee was the driving force in establishing a modern state police communication system, School based Community police services, Sex offender and DNA databank, Major Crime Investigation Concepts, Standardized Evidence Collection system, Laboratory operation Standard and Consolidated Forensic Science Services in Connecticut. He currently serves as advisor/ Consultant for more than 80 law enforcement agencies around the world. He was just appointed in 2013, as Chief Forensic Advisor for New Haven Police department.

In 1975, Dr. Lee joined the University of New Haven, where he created the school's Forensic Sciences program. He has also taught as a professor at more than a dozen universities, law schools, and medical

schools. Dr. Lee has been the recipient of numerous medals and awards. He has also been the recipient of the Distinguished Criminalist Award from the American Academy of Forensic Sciences (AAFS); the J. Donero Award from the International Association of Identification and in 1992 was elected a distinguished Fellow of the AAFS. He has also received the Lifetime Achievement Award from the American College of Forensic Examiners (ACFE) in 2000, Medal of Honor by the Ellis Island Foundation in 2004, Congressional Recognition for Outstanding services by the US Congress in 2004, Presidential Medal of Honor by the President of Croatia in 2005, Medal of Service from the Ministry of Interior, Taiwan, ROC in 2006, Medal of Service, Friendship Award from People Republic of China, and Gusi Peace Award from the Philippines in 2008.



Yung-Chi Cheng, Ph.D.

Henry Bronson Professor,
Pharmacology, Yale University
Chairman,
Consortium for the Globalization of Chinese Medicine

Prof Yung-Chi Cheng is the Henry Bronson Professor of Pharmacology at Yale University School of Medicine. He has been a leader in cancer and viral pharmacology. Currently there are five chemicals that were discovered in his laboratory that are under clinical trials for the treatment of cancer, Hepatitis B Virus, and Human Immunodeficiency Virus. His leadership in antiviral and anticancer research has been recognized by his service as a member and Chairman of the Therapeutic Study Section of NIH, a member of the Board of Scientific Counselors of the Division of Cancer Treatment of the National Cancer Institute, and a member of the AIDS Research Advisory Committee of NIH as well as many national committees in Taiwan and Hong Kong. He is also a consultant for many pharmaceutical firms and is the scientific founder of two biotechnology companies sponsored by Yale University. Throughout his career he has received numerous honours, including the Leukemia Society of America Scholar Award, the Rhodes Memorial Award from the American Association for Cancer Research, an Outstanding Investigator Award from the National Cancer Institute among many others.

Prof Cheng received his B.Sc. in Chemistry from Tunghai University of Taiwan in 1966 and his Ph.D. in Biochemical Pharmacology from Brown University under the direction and mentorship of Professor R.E. Parks, Jr. in 1972. His postdoctoral training was obtained in the Department of Pharmacology at Yale University under the direction of Professor William H. Prusoff from 1972 to 1974. He returned to Yale University as the Henry Bronson Professor of Pharmacology, Professor of Medicine and Director of the Developmental Therapeutics Program of the Yale Comprehensive Cancer Center in 1989.



Ruchin Kansal, M.B.A.

Executive Director and Head,
Business Innovation,
Boehringer Ingelheim Pharmaceuticals, Inc.

Ruchin Kansal has global experience as an executive, strategic advisor and an entrepreneur in biopharmaceutical and medical devices industry. Trained as an architect, he brings human centered design thinking to the world of business. He is adept at launching & maturing new businesses and capabilities; and driving large scale transformation programs.

Currently, he serves as the Head, Business Innovation at Boehringer Ingelheim Pharmaceuticals, Inc. In this role, he is responsible for incubating the development and evolution of strategic capabilities that adapt Boehringer Ingelheim's business to changing market environment. In addition to establishing company's first Business Innovation team, he has concurrently launched company's first Organized Customer Collaborations team, first Digital Health team, and developed its first Patient Engagement Strategy.

He is a 2016 recipient of MM&M's Top 40 Healthcare Transformers Award; invited by the White House Office of Science and Technology Policy (OSTP) for a workshop on engaging participants as partners in research, a core principle of the President's Precision Medicine Initiative; and also winner of Boehringer Ingelheim President's Award for establishing company's first Patient Engagement Vision and Strategy. He serves on the Board of Directors of Stanford Medicine X initiative.

Prior to Boehringer Ingelheim, he worked at Deloitte Consulting and Cap Gemini Ernst & Young . He holds an undergraduate degree in Architecture from Indian Institute of Technology (IIT), Roorkee and MBA from NYU-Stern.



David Cragin, Ph.D.

Associate Director,
Chemical Notification and Registration,
Merck

Dr. Dave Cragin is the Associate Director of Chemical Notification and Registration for Merck & Co. For more than 10 years, he has taught the graduate course called "Risk Assessment, Critical Thinking and Health" as an Adjunct Professor of Health Policy and Public Health for the *University of the Sciences*, Philadelphia. Since 2008, he has also taught a subset of this class as a Professor of the International Program in Pharmaceutical Engineering Management of *Peking University*, Beijing, China. In addition, he has taught risk communication in the US, China, and Europe to both industry and regulatory officials. He speaks Chinese and is knowledgeable in many languages. Previously, he was risk assessment manager and toxicology manager for several companies in the oil, chemical, and pesticide industries. Dr. Cragin is a Trustee of the *Toxicology Education Foundation*, on the Executive Board of the *Sino American Professionals Pharmaceutical Association GP*, a Past-President of the *Mid-Atlantic Society of Toxicology*, the largest chapter of the *Society of Toxicology*, and a Councilor for the *Philadelphia Association for Critical Thinking*. He received his Ph.D. in Pharmacology and Toxicology from *University of California, Davis*, his B.S. in Zoology from the *University of Rhode Island*, and is a Diplomate of the *American Board of Toxicology*.



Vincent Li, Ph.D.

Office of Life Cycle Products,
Office of Pharmaceutical Quality,
CDER, FDA

Vincent Li, Ph.D. is currently a reviewer in the Office of Life Cycle Products/Office of Pharmaceutical Quality/CDER/FDA. Prior to joining FDA, Dr. Li was the Science Excellence Director, GSK Consumer Healthcare, Shanghai, China. He has 20+ years of hands-on and management experience with Rx, OTC and generic products with several multi-national pharmaceutical companies. Dr. Li obtained his M.S. & Ph.D. in Pharmaceutics under the supervision of the late Professor Joseph Robinson at University of Wisconsin-Madison.



Chris Mix, M.D.

Executive Director,
Global Medical Sciences, Alexion

Dr. Mix is an Executive Director, Global Medical Sciences, at Alexion where he oversees the development of a candidate complement inhibitor for the treatment of atypical hemolytic uremic syndrome, and provides medical leadership for Soliris® in the same indication. Prior to joining Alexion in January 2015, Dr. Mix held roles of increasing responsibility over 12 years at Amgen, most recently as Executive Director, Global Development, for AMG 416, a candidate calcimimetic for the treatment of secondary hyperparathyroidism in patients with end-stage kidney disease. Dr. Mix has extensive mid to late-phase development experience, including the design and conduct of the pivotal AMG 416 Phase 3 trials, the Sensipar® Phase 3 EVOLVE trial – the largest and longest randomized controlled trial conducted in the dialysis population – and the Aranesp® Phase 3 TREAT and RED-HF cardiovascular outcomes trials, in the chronic kidney disease and heart failure populations, respectively. Additionally, Dr. Mix led the development of AMG 223, a candidate phosphate binder for the dialysis population, through phase 2. Dr. Mix also has extensive regulatory, payer, and commercialization experience.


Dr. Mix is a graduate of Haverford College. He received his M.D. from the University of Massachusetts Medical School in 1995 and while there, was awarded a Howard Hughes Medical Institute Research Training Fellowship. Dr. Mix completed his residency and a chief year in internal medicine at Tufts Medical Center in 1999, clinical fellowship in nephrology at the Beth Israel Deaconess Medical Center in 2001, and received an M.S. in Clinical Care Research from the Tufts University Sackler School of Biomedical Sciences in 2003.



Shaojing Hu, Ph.D.

Vice President & Chief Chemist,
Betta Pharmaceuticals Co., Ltd

Dr. Hu has extensive over 20 years drug hunting experiences in the areas of diabetes, oncology and neuroscience. Before joining Betta Pharma, he has worked for several US pharmaceutical companies, including the Institute for Diabetes Discovery and Neurogen. He is currently in charging of strategical planning and execution of Betta's R&D and IP. His team has successfully delivered multiple candidates in oncology and diabetes areas into clinical trials. He is also the head of IP department of Betta Pharma.



Ying Wang, M.S.

Member of Board of Directors,
Chongqing Lummy Pharmaceutical Co., Ltd.

Mrs. Wang has been on the Board of Directors at Chongqing Lummy Pharmaceutical Co., Ltd. since Jan. 2014. During her thirteen years at this company, Mrs. Wang had successfully lead most of the medicine registration projects and new medicine research. She was in charge of a majority of the company's clinical research and product registration. Mrs. Wang has extensive experience in drug development and clinical research management. From 2007-2015, she was the Director of New Medicine Registration Department, Director of Clinical Testing Department and Director of Technical Coordination Department in Chongqing Lummy Pharmaceutical Co. Ltd. From 2000-2006, she was the Director of New Medicine Registration Department in Chengdu Pharmmate Technology Co., Ltd. From 1988-2000, she was the physical and chemical analyst in Disease Control and Prevention Center of Chengdu Railway.



Shengju Deng, M.S.

Vice President,
Beijing Guozhi Patent Warning Consulting Co. Ltd

Shengju Deng received her master degree in Science from Peking University. She is now the research associate in patent examination and expert talent at Patent Examination Cooperation Center of the State Intellectual Property Office of China. She is currently served as the national patent information leading talent, the training expert at China Intellectual Property Training Center, project review specialist for the intellectual property strategy promotion program of Jiangsu Province, consulting expert for biomedical industry of Jinan city, consulting expert for strategic emerging industry of Hunan province and intellectual property appraisal expert for major economic activity of Shanxi province. Ms. Deng has been engaged in substantial patent examination in pharmaceutical and chemical field since July 2002 and was designated to Beijing Guozhi Patent Warning Consulting Co. Ltd to work on patent technical and legal counseling since 2003. From September 2011 to December 2012, she was sent to work at the intellectual property court of Beijing First Intermediate People's Court and still act as jury of the same court to this day.



Anthony Sabatelli, J.D., Ph.D.

Partner,
Dilworth IP-Intellectual Property Law

Dr. Anthony Sabatelli is an experienced patent practitioner and former biotech executive and research scientist, who provides insightful, practical, and business-oriented service to his clients. Although his primary focus is on biotechnology and the pharmaceutical industry, he has had broad experience across many areas of the chemical field including formulations and polymers. Dr. Sabatelli learned early on in his career that the successful patent practitioner must be an "Exclusivity Attorney" adept at understanding the complex interplay of patent, regulatory, and product life-cycle issues. He is versed in the Hatch-Waxman and regulatory laws relevant to pharmaceutical practice. Having spent most of his career in-house, as both a research scientist and as a patent attorney, Dr. Sabatelli appreciates the needs and perspective of the inventors in the lab and the in-house attorneys who seek to protect those inventions. He listens to his clients to help them create robust, yet practical, portfolios, whether comprising a single patent case or several hundred patents. Above all, he enjoys sharing his passion for his work with his clients and colleagues. Dr. Sabatelli has a strong interest in and commitment to education and is currently an Adjunct Professor of Chemistry at the University of New Haven. He is a Member of the Board of Governors of Yale University and currently serves as Immediate Past-Chairman of the Yale Graduate School Alumni Association.



Alan J. Morrison, J.D., M. Phil.

Founder,
Law Offices of Alan J. Morrison

Alan J. Morrison founded the Law Offices of Alan J. Morrison in 2014. Prior to that, he was a partner at the New York firms of Cozen O'Connor, Cohen, Pontani, Lieberman & Pavane LLP and Cooper & Dunham LLP, and served as in-house counsel at Johnson & Johnson in New Brunswick, New Jersey. Mr. Morrison counsels his clients in the biotechnology and pharmaceutical fields regarding patents and related transactional law. In his more than 20 years of practice, Mr. Morrison has represented some of the world's largest, most prestigious and most innovative companies and institutions.

Mr. Morrison is also a faculty member in the Department of Biological Sciences at Columbia University where he teaches two graduate courses – “Biotechnology Law” and “Ethics in Biopharmaceutical Patent and Regulatory Law.” These courses, which he designed, are the first of their kind at Columbia.

Mr. Morrison earned a B.A. in biochemistry from the University of California, Berkeley, in 1984; an M.S. in biological chemistry from the University of Michigan in 1986; an M.Phil. in biochemistry and molecular biophysics from Columbia University in 1988; and a J.D. from the Benjamin N. Cardozo School of Law, Yeshiva University in 1992.



Jianying Hu, Ph.D.

Program Director,
Center for Computational Health,
IBM T.J. Watson Research Center

Jianying Hu is a Distinguished Research Staff Member and Program Director of Center for Computational Health at IBM T. J. Watson Research Center, NY. Prior to joining IBM in 2003 she was with Bell Labs at Murray Hill, New Jersey. Dr. Hu received the Ph.D. degree in Computer Science from SUNY Stony Brook in 1993. Her main research interests include machine learning, data mining, statistical pattern recognition, and signal processing, with applications to healthcare analytics, medical informatics, business analytics, document analysis, and multimedia content analysis. Her recent focus has been on leading research efforts in developing advanced machine learning, data mining and visual analytics methodologies for deriving data-driven insights from real world healthcare data to facilitate “learning health systems”. Dr. Hu has published over 100 technical articles and holds 27 patents. She has served as associate editor for IEEE Transactions on Pattern Analysis and Machine Intelligence, IEEE Transactions on Image Processing, Pattern Recognition, and International Journal for Document Analysis and Recognition. Dr. Hu is a fellow of IEEE (class of 2015), a fellow of the International Association of Pattern Recognition (class of 2010), and a recipient of the Asian American Engineer of the Year Award (class of 2013).



Qichao Zhu, Ph.D.

Associate Professor
Genetics & Genomic Science
Icahn School of Medicine at Mount Sinai Hospital

More than 20 years in pharmaceutical industry and academic area and has concentrated on top-notch bioinformatics platform designs and implementations and big data analysis for drug discovery and development. More recently his research has been focused on translational research, particularly in precision medicine on cancer therapy.



Weibin Chen, Ph.D.

Director, Scientific Operations
Waters Corporation

Weibin Chen is a director in the scientific operations (SO) organization of Waters Corporation (Milford, MA). He has been actively involved in the development of new LC/MS-based solutions for pharmaceutical analysis for more than 15 years. Currently, he is responsible for managing scientific projects that are designed to deliver analytical solutions to address the challenges and unmet technical needs in the pharmaceutical industry by LC/MS technologies. Weibin has a Ph.D. degree in Analytical Chemistry from Purdue University and published nearly 40 peer-reviewed scientific papers/book chapters on pharmaceutical analysis.



Min Li, Ph.D.

Vice President, Analytical Operation
Huahai Pharmaceutical Co., Ltd

Dr. Min Li received his PhD in Organic Chemistry from Johns Hopkins University in 1991. He did postdoctoral research in medicinal chemistry at College of Pharmacy, University of Illinois at Chicago. Starting from 1995, he had worked for several multi-national pharmaceutical companies. He was a Principal Scientist at Roche (1995 - 1998), Scientific Fellow at Merck (1998 - 2005), manager at Schering-Plough (2005 - 2009), and Associate Director at Analytical Chemistry in Development and Supply – Supply Analytical Sciences (ACDS-SAS) Department of Merck (2009 – 2014).

Over the years, Dr. Li has led technical teams of senior-level scientists for various analytical and pharmaceutical manufacturing process investigations and troubleshooting, impurity peak identification, study of drug degradation chemistry, analytical method development, validation, specification setting, and support for new drug filing.

Since September 2014, Dr. Li has taken the position of Vice President for Analytical Operation at Huahai Pharmaceutical. His current responsibilities at Huahai include 1) Providing technical leadership and guidance to analytical R&D in Huahai. 2) Leading the API Analytical R&D organization at Huahai's headquarters. 3) Leading the API Quality Control Laboratories. 4) Established and leading the Center of Excellence for Modern Analytical Technologies (CEMAT, a group created for solving the most challenging technical problems from R&D to scale-up and commercial production).

Dr. Li is a leading expert in drug degradation chemistry and he published a single-authored book, "Organic Chemistry of Drug Degradation" (by the Royal Society of Chemistry, Cambridge, UK) in 2012, which has become one of the best-selling books in RSC's Drug Discovery Series. He is the first/communicating author of more than 40 publications in organic, medicinal, bioconjugate, and analytical chemistry (including mass spectrometry). Dr. Li was president of Sino-American Pharmaceutical Professional Association (SAPA) between 2003 and 2004. He currently is a member of the Chemical Medicines Monographs Expert Committee of USP.



James (Tianquan) Jin, Ph.D.

Vice President,
Biocytogen

Dr. James Jin received his PhD of virology at Wuhan University in 1997. He had his postdoctoral training in Colorado State University and University of Illinois at Chicago. He worked as a research assistant professor in University of Illinois at Chicago from 2005 to 2010. In 2010, he was recruited to Advanced Cell Technology, Inc. as a senior scientist to study the human ES cell differentiation. His research covers virology, immunology, proteomics, protein structure, human stem cell, and gene-targeting animal model. Dr. Jin joined Biocytogen as the Vice President in 2011. His role is to oversee Biocytogen in USA.



Meifang Xu, M.S., M.B.A.

Chairman,
the Community Charity Foundation of Jiading Industrial Zone

Ms. Xu Meifang has 10 years of working experience in biopharmaceutical field. In 2004, she got John Innes Center full scholarship and obtained bioinformatics master degree of University of East Anglia. In 2007, she went to Germany Coburg University to study financial management and obtained MBA degree in 2009. Since 2011, she has been worked in Jiading advanced technology innovation and business center for incubation and investment work. In 2015, she started the first phase of BIO-CUBE Park, a prof-CRO platform, so far, which has a 100% occupancy rate and a successful development. In March 2016, she started the second phase of BIO-CUBE Park, which focused on diagnostic reagent and medical device R&D. In 2013, she obtained the title of Jiading District's leading talent. She is also chairman of the community charity foundation of Jiading industrial zone.



John Tan, Ph.D.

President,
Kelun U.S. Pharmaceutical Research Institute

Kelun US Pharmaceutical Research Institute is the subsidiary of Kelun Pharmaceutical Research Institute, that manages Kelun's US operation in four functional areas – generic R&D, innovative small-molecule and biologics R&D, global BD - and the subsidiary Klus Pharma Inc. Previously Dr. Tan served at Memorial Sloan-Kettering Cancer Center and Merck & Co. for over 15 years, leading various drug discovery teams in infectious diseases, osteoporosis, anemia, cardiovascular, central nervous system, diabetes, endocrine, and oncology, as well as managing strategic partnership activities. Dr. Tan has rich experience in the biopharmaceutical industry, including R&D, corporate management, IP strategy, due diligence evaluation, company start-up, partnership and licensing deals. He is a recipient of US Department of Defense *Era of Hope* Cancer Research Award and Merck Excellence of Research Awards. Dr. Tan has been invited to give more 30 lectures in US, Asia and Europe. Dr. Tan received a Ph.D. from Columbia University.


SAPA-CT

Presidents

Yongmei Li, Ph.D.
(2014-2015)



Liang Luo, Ph.D.
(2015-2016)



Steven Yu, Ph.D., M.B.A.
(2016-2017)




Conference Committee

Jasmin Huang



Na Li, Ph.D.



Jingwei Sun



Ting Yi, Ph.D.



Mingzhu Yin



Chao Zhang



Mingqing Cai

Li Wang

Xiang Gao

Yingkai Wang

Fei Han

Yirong Wang

Rongliang Lou

Zhongyu Wang

Qiao Lu

Xiaobo Zhong

Xiuling Lu

Jin Zhou

Xiaohui Mei

Qichao Zhu

Ruobing Xia

Sponsors

Bio-Pharmaceutical Intellectual Property Fund
Kelun US Pharmaceutical Research Institute
Shanghai Chenpon Pharmaceutical Technology Co. Ltd.
Boehringer Ingelheim Pharmaceuticals
Dilworth IP - Intellectual Property Law
Huahai Pharmaceutical Co., Ltd
Waters Corporation
United Airlines
Biocytogen
GenScript
Genotech Matrix
Zhejiang Beta Pharma., Inc.

Registration available onsite or online:

<http://www.eventbrite.com/e/2016-sapa-ct-3rd-annual-conference-tickets-27425527491>

- Membership: \$30/year, \$200/lifetime (for registered members, conference registration and lunch are free. Dinner is not included.)
- Conference registration, including a complementary lunch: \$30
- Conference registration, including a complementary lunch and dinner: \$70



Website: <http://www.sapa-ct.org>

LinkedIn: [Friends and Members of SAPA-Connecticut](#)

Email: contact@sapa-ct.org